Human Immunodeficiency Virus (HIV) Infection

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

Strategies to AchieVe Viral Suppression for Youth With HIV

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

Empowering Knowledge, Self-Testing & Resilience Through Innovative Methods for HIV

Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis

Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Interventions to Improve HIV Antiretroviral Therapy Adherence

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients

Folinic Acid and Vascular Reactivity in HIV

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers